Cite

    Wildiers, H., Meyskens, T., Marréaud, S., Lago, L. D., Vuylsteke, P., Curigliano, G., Waters, S., Brouwers, B., Meulemans, B., Sousa, B., Poncet, C., & Brain, E. (2022). long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression. Breast, 64, 100–111. http://access.bl.uk/ark:/81055/vdc_100158012670.0x00003d